Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Conditions
Brief summary
This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Rintatolimod may stimulate the immune system. Giving celecoxib, recombinant interferon alfa-2b, and rintatolimod may work better at treating colorectal cancer that has spread to the liver.
Detailed description
PRIMARY OBJECTIVES: I. To determine the impact of a chemokine-modulatory regimen on the immune microenvironment of colorectal liver metastases, specifically the changes in the ratio between cytotoxic T-lymphocyte (CTL) marker (CD8a gene expression) to regulatory T cell (Treg) markers (FoxP3 gene expression). SECONDARY OBJECTIVES: I. Estimate the objective response rate of a chemokine-modulatory regimen in metastatic colorectal cancer (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1). II. Examine the safety and tolerability profile of the combination of recombinant interferon alfa-2b (interferon alpha-2b), rintatolimod, and celecoxib when given as chemokine modulation to colorectal cancer patients prior to surgical resection using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0). TERTIARY OBJECTIVES: * Estimate the median progression free survival of a chemokine-modulatory regimen in metastatic colorectal cancer * Estimate overall survival in participants with recurrent and/or metastatic unresectable colorectal cancer who received the chemokine-modulatory regimen * Comparison (using RT-PCR, immunofluorescence \[IF\] and immunohistochemistry \[IHC\] on serial sections) of the metastatic tissue specimen with regard to total numbers of infiltrating T cells, their CD4/CD8 ratios, frequencies of FoxP3 cells, and the expression of chemokine receptors on CD4+ and CD8+ T cells (CXCR3, CCR5, CCR4, CCR6, and CXCR4) * Evaluate the local expression of effector T cells (Teff)-attracting chemokines (CCR5, CXCL9, CXCL10 and CXCL11) and Treg-favoring chemokines (CCL22 and CXCL12) using IF and RT-PCR. OUTLINE: Patients receive celecoxib orally (PO) twice daily (BID), recombinant interferon alfa-2b intravenously (IV) over 20 minutes, and rintatolimod IV QD on days 1, 2,3,8,9,10,15,16 and 17 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 12 months.
Interventions
DRUGCelecoxib
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALRecombinant Interferon Alfa-2b
Given IV
DRUGRintatolimod
Given IV
Sponsors
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recurrent and/or metastatic unresectable colorectal cancer with hepatic metastases * Hepatic metastases present which are amenable to biopsy * Prior treatment with, contra-indication to or refusal of a fluoropyrimidine, irinotecan, oxaliplatin and an anti-EGFR targeted therapy (if RAS wild-type \[wt\]) as well as a PD-1 or PD-L1 targeted drug if MSI-H/dMMR * No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment * An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Have measurable disease per RECIST 1.1 criteria present * Ability to swallow and retain oral medication * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Platelet \>= 75,000/uL * Hemoglobin \>= 9 g/dL * Hematocrit \>= 27% * Absolute neutrophil count (ANC) \>= 1500/uL * Creatinine \< = institutional upper limit of normal (ULN) OR * Creatinine clearance \>= 50 mL/min for patients with creatinine levels greater than ULN * Total bilirubin =\< 1.5 X institutional ULN or for patients with known Gilbert's Syndrome total bilirubin \<= 3 x ULN * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional ULN * Plasma amylase =\< 1.5 X institutional ULN * Lipase =\< 1.5 X institutional ULN * Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment * Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation * Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening * Untreated central nervous system (CNS) metastases * Cardiac risk factors including: * Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent * Patients with a New York Heart Association classification of III or IV * History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded * Prior allergic reaction or hypersensitivity to celecoxib, or non-steroidal antiinflammatory drugs (NSAIDs) or any study agents which would prevent completion of protocol therapy * Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average; low-dose aspirin not exceeding 100 mg/day is permitted; patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no wash out period is required * Received an investigational agent within 30 days prior to enrollment * Unwilling or unable to follow protocol requirements * Patients with known serious mood disorders * Any additional condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive the study drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions | Baseline up to 12 months | The TILs will be summarized by time-point (pre-/post-treatment) using the mean, median, standard deviation; and graphically using dot-plots. The TIL of interest is CD8a expression, which is reported as the mean fold change from pre-treatment (i.e. post treatment / pre treatment). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Indicated Grade Adverse Event | Up to 12 months | Safety profile will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment. The highest grade treatment related AE is provided (per Common Terminology Criteria for Adverse Events version 4.0). |
| Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 | Up to 12 months | Will be treated as binary data and summarized using frequencies and relative frequencies; with the ORR estimated using a 90% confidence interval obtained using Jeffrey's prior method. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | From the start of treatment until disease progression (defined by RECIST 1.1) or last-follow-up, assessed up to 12 months | Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods. |
| Overall Survival | From the start of treatment until death due to any cause or last follow-up, assessed up to 12 months | Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV QD over 20 minutes, and rintatolimod IV QD on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity.
Celecoxib: Given PO
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Alfa-2b: Given IV
Rintatolimod: Given IV | 15 |
| Total | 15 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Did not meet eligibility criteria | 4 |
| Overall Study | Disease progression | 3 |
Baseline characteristics
| Characteristic | Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) |
|---|---|
| Age, Continuous | 60.5 years STANDARD_DEVIATION 9.9 |
| Clinical Stage Not Reported | 0 Participants |
| Clinical Stage Stage I | 0 Participants |
| Clinical Stage Stage II | 0 Participants |
| Clinical Stage Stage III | 0 Participants |
| Clinical Stage Stage IV | 15 Participants |
| Line of Treatment Fifth or More Line | 4 Participants |
| Line of Treatment Fourth Line | 6 Participants |
| Line of Treatment Third Line | 5 Participants |
| Location of Disease Cecum | 1 Participants |
| Location of Disease Colon, NOS | 7 Participants |
| Location of Disease Rectum, NOS | 6 Participants |
| Location of Disease Sigmoid Colon | 1 Participants |
| Prior Radiation | 6 Participants |
| Prior Surgery | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 14 Participants |
| RAS Type KRAS | 5 Participants |
| RAS Type NRAS | 3 Participants |
| RAS Type Wild-type | 7 Participants |
| Region of Enrollment United States | 15 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 8 / 15 |
| other Total, other adverse events | 14 / 15 |
| serious Total, serious adverse events | 3 / 15 |
Outcome results
Primary
Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions
The TILs will be summarized by time-point (pre-/post-treatment) using the mean, median, standard deviation; and graphically using dot-plots. The TIL of interest is CD8a expression, which is reported as the mean fold change from pre-treatment (i.e. post treatment / pre treatment).
Time frame: Baseline up to 12 months
Population: 3 patients did not have post treatment biopsies, and were considered unevaluable for the primary endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions | 7.25 fold change | Standard Deviation 13.79 |
p-value: 0.046t-test, 1 sided
Secondary
Number of Participants With Indicated Grade Adverse Event
Safety profile will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment. The highest grade treatment related AE is provided (per Common Terminology Criteria for Adverse Events version 4.0).
Time frame: Up to 12 months
Population: All patients that received study treatment.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | No Treatment Related AE Reported | 1 Participants |
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | Grade I | 6 Participants |
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | Grade II | 7 Participants |
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | Grade III | 1 Participants |
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | Grade IV | 0 Participants |
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Number of Participants With Indicated Grade Adverse Event | Grade V | 0 Participants |
Secondary
Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Will be treated as binary data and summarized using frequencies and relative frequencies; with the ORR estimated using a 90% confidence interval obtained using Jeffrey's prior method.
Time frame: Up to 12 months
Population: Evaluated in subjects evaluable for the primary end-point.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 | 0 Participants |
Other Pre-specified
Overall Survival
Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.
Time frame: From the start of treatment until death due to any cause or last follow-up, assessed up to 12 months
Population: Evaluated in subjects evaluable for the primary end-point.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Overall Survival | 10.5 Months |
Other Pre-specified
Progression Free Survival
Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.
Time frame: From the start of treatment until disease progression (defined by RECIST 1.1) or last-follow-up, assessed up to 12 months
Population: Evaluated in subjects evaluable for the primary end-point.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) | Progression Free Survival | 1.5 Months |